EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding...
Transcript of EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding...
![Page 1: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/1.jpg)
EMEA experience with endpoints for EMEA experience with endpoints for Oncology drug approval Oncology drug approval
EMEA/CHMP Biomarkers Workshop 16 December 2005
Francesco Pignatti, MDFrancesco Pignatti, MDThe European Medicines Agency (EMEA)The European Medicines Agency (EMEA)
London London -- United KingdomUnited Kingdom
![Page 2: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/2.jpg)
2
ContentsContents
Endpoints commonly used in oncologyLegal requirementsEMEA Experience with oncology drugsEMEA Experience with oncology drugs––Endpoints in pivotal trials for registrationEndpoints in pivotal trials for registration––Common reasons for rejectionCommon reasons for rejection
FDA ExperienceFDA ExperienceEU oncology guideline (EU oncology guideline (NewNew))––OS OS vv PFSPFS
SummarySummary
![Page 3: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/3.jpg)
3
--From initial onset in a high risk populationFrom initial onset in a high risk populationReduction in the risk of diseaseReduction in the risk of diseaseProtection against toxicity with no decrease in survivalProtection against toxicity with no decrease in survival--Patient Benefit (palliation, improvement in symptoms)Patient Benefit (palliation, improvement in symptoms)--Tumor (usually based on imaging results)Tumor (usually based on imaging results)ResponseResponse
--Onset or worsening of disease related symptomsOnset or worsening of disease related symptoms--Tumor (usually based on imaging results)Tumor (usually based on imaging results)
--ProgressionProgression--freefree--DiseaseDisease--freefree--OverallOverallSurvivalSurvival
Clinical trial endpoints commonly used in oncology
![Page 4: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/4.jpg)
4
Legal requirementsLegal requirements
Randomized controlled clinical trials (if possible)Randomized controlled clinical trials (if possible)Versus placebo and versus an established Versus placebo and versus an established treatment (as appropriate)treatment (as appropriate)Minimize bias and uncertaintyMinimize bias and uncertainty
AuthorisationAuthorisation refused if medicinal productrefused if medicinal productEfficacy insufficiently substantiated or lackingEfficacy insufficiently substantiated or lackingHarmfulHarmful……
![Page 5: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/5.jpg)
5
ICH E8 and E9ICH E8 and E9
Confirmatory trials Confirmatory trials should demonstrateshould demonstrateclinical benefitclinical benefitThe primary endpoint The primary endpoint
Should Should provide the most clinically relevant provide the most clinically relevant and convincing evidenceand convincing evidenceValid and reliable measure of some Valid and reliable measure of some clinically relevant and important treatment clinically relevant and important treatment benefitbenefit
![Page 6: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/6.jpg)
The EMEA experienceThe EMEA experience
![Page 7: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/7.jpg)
7
16 (64%)16 (64%)Cytotoxic agent Cytotoxic agent aa
2 (8%)2 (8%)Endocrine agent Endocrine agent cc
7 (28%)7 (28%)Monoclonal antibody, Monoclonal antibody, biopharmaceuticals biopharmaceuticals bb
N = 25N = 25
EMEA Experience: Approved New AgentsEMEA Experience: Approved New Agents
a – Alimta,Caelyx, DepoCyte, Foscan, Glivec, Hycamtin, Litak, Myocet, Panretin, Paxene, Targretin, Taxotere, Temodal, Trisenox, Velcade, Xeloda
b – Avastin, Beromun, Erbitux, Herceptin, MabCampath, Mabthera, Zevalin
c - Fareston, Faslodex
Pignatti et al. Crit Rev Oncol Hematol. 2002 May;42(2):123-35. Chaplin et al. ESMO 2004. Pignatti, DIA Annual Meeting 2005.
![Page 8: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/8.jpg)
8
Approved Approved IndicationsIndicationsSite of primary and endpointsSite of primary and endpoints
13 (28%) PFS, RR 13 (28%) PFS, RR 13 (28%) OS, PFS, RR 13 (28%) OS, PFS, RR 5 (11%) RR5 (11%) RR5 (11%) OS5 (11%) OS3 (6%) OS, RR3 (6%) OS, RR3 (6%) OS, PFS, RR3 (6%) OS, PFS, RR3 (6%) PFS, RR3 (6%) PFS, RR1 (2%) RR 1 (2%) RR 1 (2%) OS1 (2%) OS
Hematological Hematological malignancymalignancyBreastBreastSarcoma Sarcoma Lung cancerLung cancerColorectalColorectalBrain cancerBrain cancerOvarianOvarianHead and neckHead and neckProstateProstate
N = 47 EndpointsN = 47 Endpoints
Indications: includes new drug application and extensions of indication
![Page 9: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/9.jpg)
9
Design of pivotal trials (N=47 approved Design of pivotal trials (N=47 approved indicationsindications))
Reason for accepting designReason for accepting designnnEndpointEndpointDesignDesign
OSOS
PFSPFS
RRRR
PFSPFS
RRRR
99
1414
outstanding activity outstanding activity AND AND
no established treatmentsno established treatments
4 *4 *Phase III Phase III RCTRCT
22
1818Phase IIPhase II
RR: 22 (47%) PFS: 16 (34%) OS: 9 (19%)RR: 22 (47%) PFS: 16 (34%) OS: 9 (19%)
* variation of established drugs
![Page 10: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/10.jpg)
10
Pivotal trials: primary endpoints and design Pivotal trials: primary endpoints and design (N=48 approved indications)
1995-1999 (N=20)
2000-2004(N=28)
Endpoint OS 2 (11%) 6 (21%)
PFS 3 (16%) 11 (39%)
RR 15 (79%) 11 (39%)
RCT 11 (55%) 19 (68%)
0
2
4
6
8
10
12
1995 2000Submission (Year)
No.
of i
ndic
atio
ns
RROS/PFSRCT
Note: Ongoing applications excludedAbbreviations: OS overall survival, PFS progression-free survival, RCT randomized controlled trial
DIA Annual Meeting 2005.
![Page 11: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/11.jpg)
11
RejectedRejected / withdrawn indications (N=13)/ withdrawn indications (N=13)
OSOS
RRRR
RRRR
EndpointEndpoint Reason for rejectionReason for rejectionnnDesignDesign
22
non randomisednon randomisedAND AND
no outstanding activityno outstanding activity
-- no effectno effect-- wrong comparatorwrong comparator-- dose justificationdose justification
-- low level of responselow level of response-- inadequate controlinadequate control-- target /size of populationtarget /size of population-- dose justificationdose justification
66Phase III Phase III
55Phase IIPhase II
Eur J Clin Pharmacol. 2002 Dec;58(9):573-80.
![Page 12: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/12.jpg)
12
FDA experienceFDA experience
What endpoints have been used in oncology What endpoints have been used in oncology registration studies?registration studies?Presentation/Publication: Presentation/Publication:
J J ClinClin OncolOncol. 2003 Mar 15;21(6):1066. 2003 Mar 15;21(6):1066--73 73
![Page 13: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/13.jpg)
13
Primary Endpoints for New Molecular EntitiesPrimary Endpoints for New Molecular Entities
Accelerated Regular
Response Rate 93% 53% Survival 0 % 12% Time to Progression 7% 20%
Symptom benefit 0% 12% Other 7% 32%
S. Hirschfeld, presentation to the CBER Office of Cellular Tissue and Gene Therapy
seminar on November 16
Talarico, et al. ASCO 2005
Proportion of clinical studies used to support approval using various endpoints
Note: Totals are not 100% due to multiple endpoints.
![Page 14: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/14.jpg)
EU oncology guidelineEU oncology guideline
“Guideline on Evaluation of Anticancer “Guideline on Evaluation of Anticancer Medicinal Products in Man” (July 2003)Medicinal Products in Man” (July 2003)
http://www.emea.eu.int/pdfs/human/ewp/020595en.pdfhttp://www.emea.eu.int/pdfs/human/ewp/020595en.pdf
![Page 15: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/15.jpg)
15
NonNon--cytotoxic compoundscytotoxic compounds
NonNon--cytotoxic compounds cytotoxic compounds ⇒⇒ Very heterogeneous Very heterogeneous groupgroup
AntihormonalAntihormonal agents, agents, antisenseantisense compounds, compounds, signal transduction, signal transduction, angiogenesis or cell angiogenesis or cell cycle inhibitors, immune modulators cycle inhibitors, immune modulators ……
Toxicity may not be an appropriate endpoint in Toxicity may not be an appropriate endpoint in dose and schedule finding trialsdose and schedule finding trialsORR: may not be an appropriate measure of antiORR: may not be an appropriate measure of anti--tumortumor activityactivityUse of predefined PD targetsUse of predefined PD targets
Biological validationBiological validationConfirmation of PDConfirmation of PD--efficacyefficacy
![Page 16: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/16.jpg)
16
Revision 3 of the anticancer guidelineRevision 3 of the anticancer guideline
NonNon--cytotoxic Compounds: cytotoxic Compounds: Focus on exploratory studiesFocus on exploratory studiesPhase I, dose and schedule finding trialsPhase I, dose and schedule finding trials–– Endpoints, healthy subjects studiesEndpoints, healthy subjects studies
Phase II, therapeutic exploratory studiesPhase II, therapeutic exploratory studies–– Use of TTP instead of response rateUse of TTP instead of response rate–– Randomised phase II studiesRandomised phase II studies–– Within patient comparisonsWithin patient comparisons
Phase III, confirmatory studies (all types of agents)Phase III, confirmatory studies (all types of agents)Interim analyses / data maturityInterim analyses / data maturityOS as primary endpoint, not RROS as primary endpoint, not RRPossible: Possible: PFS when clinically relevant, sPFS when clinically relevant, symptom controlymptom control
![Page 17: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/17.jpg)
17
OS or PFS?OS or PFS?
OS provides strong evidence of efficacy (mortality) OS provides strong evidence of efficacy (mortality) PFS if it measures clinical benefit (not a good PFS if it measures clinical benefit (not a good surrogate for OS)surrogate for OS)
Symptomatic progression Symptomatic progression v.v. radiological onlyradiological onlyUse PFS when further lines of therapy modify OSUse PFS when further lines of therapy modify OSUse OS when PFS Use OS when PFS ≈≈ OS, or major differences in OS, or major differences in toxicitytoxicityWhat is the smallest clinically relevant and What is the smallest clinically relevant and convincing effect in terms of PFS? convincing effect in terms of PFS? Many methodological issues to avoid biasMany methodological issues to avoid bias
![Page 18: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/18.jpg)
18
Alternative primary endpoints?Alternative primary endpoints?
TTP, TTF or EFS generally not adequateTTP, TTF or EFS generally not adequateOther measures of patient benefit (e.g. limbOther measures of patient benefit (e.g. limb--saving surgery, access to BMT)saving surgery, access to BMT)Tumour markers (e.g., MTumour markers (e.g., M--protein) may be protein) may be used to define PD (together with other used to define PD (together with other variables)variables)
![Page 19: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/19.jpg)
19
Summary/ConclusionsSummary/Conclusions
Strict legal requirements/guidelines to demonstrate Strict legal requirements/guidelines to demonstrate benefitbenefitWrong design or lack of efficacy the most important Wrong design or lack of efficacy the most important reason for rejectionreason for rejectionFlexible assessment of designs and endpointsFlexible assessment of designs and endpoints
RR when outstanding activity, no treatment RR when outstanding activity, no treatment availableavailableFrom OS to other measures of benefitFrom OS to other measures of benefit
Non cytotoxic agentsNon cytotoxic agentsFocus on exploratory studiesFocus on exploratory studies
Role of CHMP scientific adviceRole of CHMP scientific advice
![Page 20: EMEA experience with endpoints for Oncology drug approval · PFS RR PFS RR 9 14 outstanding activity AND no established treatments 4 * Phase III RCT 2 18 Phase II RR: 22 (47%) PFS:](https://reader033.fdocuments.us/reader033/viewer/2022051815/603d4f6c4becab0c385ae9d8/html5/thumbnails/20.jpg)
20
AcknowledgementsAcknowledgements
Eric AbadieEric Abadie
Myriam ChapelinMyriam Chapelin
Steven Steven HirschfeldHirschfeld
Bertil JonssonBertil Jonsson
Michel MartyMichel Marty